Pseudotyped influenza A virus as a vaccine for the induction of heterotypic immunity

Journal of Virology

Volumn 86, Issue 24, 2012, Pages 13397-13406

  Powell, Timothy J ^a   Silk, Jonathan D ^b   Sharps, Jane ^c   Fodor, Ervin ^c   Townsend, Alain R M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORE PROTEIN; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; SIALIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HETEROTYPIC IMMUNITY; IMMUNITY; IMMUNOFLUORESCENCE; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; LUNG; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; WEIGHT REDUCTION;

ADMINISTRATION, INHALATION; ANIMALS; ANTIBODIES, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEUTRALIZATION TESTS; T-LYMPHOCYTES;

INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE;

EID: 84870676890     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01820-12     Document Type: Article

References (70)

1. Alsharifi M, et al. 2009. Intranasal flu vaccine protective against seasonal and H5N1 avian influenza infections. PLoS One 4:e5336. doi:10.1371/journal.pone.0005336.
2. Anhlan D, Hrincius ER, Scholtissek C, Ludwig S. 2012. Introduction of silent mutations into the NP gene of influenza A viruses as a possible strategy for the creation of a live attenuated vaccine. Vaccine 30:4480-4489.
3. Belshe RB, Ambrose CS, Yi T. 2008. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. Vaccine 26(Suppl 4):D10-D16.
4. Belshe RB, Coelingh K, Ambrose CS, Woo JC, Wu X. 2010. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 28:2149-2156.
5. Bodewes R, et al. 2011. Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets. J. Virol. 85:2695-2702.
6. Brown LE, Kelso A. 2009. Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes. Immunol. Cell Biol. 87:300-308.
7. Castro JF, et al. 2005. Evaluation of immunogenicity and side effects of triple viral vaccine (MMR) in adults, given by two routes: subcutaneous and respiratory (aerosol). Vaccine 23:1079-1084.
8. Chen J, et al. 1998. Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation. Cell 95:409-417.
9. Cowling BJ, et al. 2010. Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong. Clin. Infect. Dis. 51:1370-1379.
10. Demaison C, et al. 2002. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum. Gene Ther. 13:803-813.
11. De Santo C, et al. 2008. Invariant NKT cells reduce the immunosuppressive activity of influenzaAvirus-induced myeloid-derived suppressor cells in mice and humans. J. Clin. Invest. 118:4036-4048.
12. Doherty PC, Kelso A. 2008. Toward a broadly protective influenza vaccine. J. Clin. Invest. 118:3273-3275.
13. Doherty PC, Turner SJ, Webby RG, Thomas PG. 2006. Influenza and the challenge for immunology. Nat. Immunol. 7:449-455.
14. Epstein SL, Price GE. 2010. Cross-protective immunity to influenza A viruses. Expert Rev. Vaccines 9:1325-1341.
15. Ferguson NM, Galvani AP, Bush RM. 2003. Ecological and immunological determinants of influenza evolution. Nature 422:428-433.
16. Fodor E, et al. 1999. Rescue of influenza A virus from recombinant DNA. J. Virol. 73:9679-9682.
17. Francis T, Magill TP. 1935. Immunological studies with the virus of influenza. J. Exp. Med. 62:505-516.
18. Francis T, Shope RE. 1936. Neutralization tests with sera of convales cent or immunized animals and the viruses of swine and human influenza. J. Exp. Med. 63:645-653.
19. Furuya Y, et al. 2010. Cytotoxic T cells are the predominant players providing cross-protective immunity induced by {gamma}-irradiated influenza A viruses. J. Virol. 84:4212-4221.
20. Grebe KM, Yewdell JW, Bennink JR. 2008. Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect. 10:1024-1029.
21. Grimm D, et al. 2007. Replication fitness determines high virulence of influenza A virus in mice carrying functional Mx1 resistance gene. Proc. Natl. Acad. Sci. U. S. A. 104:6806-6811.
22. Harlow E, Lane D. 1988. Antibodies: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
23. Herfst S, et al. 2012. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336:1534-1541.
24. Hoft DF, et al. 2011. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J. Infect. Dis. 204:845-853.
25. Hogan RJ, et al. 2001. Activated antigen-specific CD8 T cells persist in the lungs following recovery from respiratory virus infections. J. Immunol. 166:1813-1822.
26. Imai M, et al. 2012. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486:420-428.
27. Kok WL, et al. 2012. Pivotal advance: invariant NKT cells reduce accumulation of inflammatory monocytes in the lungs and decrease immunepathology during severe influenzaAvirus infection. J. Leuk. Biol. 91:357-368.
28. Lau YF, Wright AR, Subbarao K. 2012. The contribution of systemic and pulmonary immune effectors to vaccine-induced protection from H5N1 influenza virus infection. J. Virol. 86:5089-5098.
29. Lee LY, et al. 2008. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J. Clin. Invest. 118:3478-3490.
30. Li GM, et al. 2012. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc. Natl. Acad. Sci. U. S. A. 109:9047-9052.
31. Liang S, Mozdzanowska K, Palladino G, Gerhard W. 1994. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J. Immunol. 152:1653-1661.
32. Lin YL, Askonas BA. 1981. Biological properties of an influenza A virusspecific killer T cell clone. Inhibition of virus replication in vivo and induction of delayed-type hypersensitivity reactions. J. Exp. Med. 154:225-234.
33. Marsh GA, Hatami R, Palese P. 2007. Specific residues of the influenza A virus hemagglutinin viral RNA are important for efficient packaging into budding virions. J. Virol. 81:9727-9736.
34. Martinez-Sobrido L, et al. 2010. Hemagglutinin-pseudotyped green fluorescent protein-expressing influenza viruses for the detection of influenza virus neutralizing antibodies. J. Virol. 84:2157-2163.
35. Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk HD. 2003. Overexpression of the alpha-2,6-sialyltransferase inMDCKcells increases influenza virus sensitivity to neuraminidase inhibitors. J. Virol. 77:8418-8425.
36. Matrosovich M, Matrosovich T, Garten W, Klenk HD. 2006. New low-viscosity overlay medium for viral plaque assays. Virol. J. 3:63.
37. McMichael AJ, Gotch FM, Dongworth DW, Clark A, Potter CW. 1983. Declining T-cell immunity to influenza, 1977-82. Lancet ii:762-764.
38. Nguyen HH, et al. 1999. Heterosubtypic immunity to lethal influenzaAvirus infection is associated with virus-specific CD8(+) cytotoxic T lymphocyte responses induced in mucosa-associated tissues. Virology 254:50-60.
39. Okuno Y, Isegawa Y, Sasao F, Ueda S. 1993. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J. Virol. 67:2552-2558.
40. Powell TJ, et al. 2012. Identification of H5N1-specific T-cell responses in a high-risk cohort in Vietnam indicates the existence of potential asymptomatic infections. J. Infect. Dis. 205:20-27.
41. Powell TJ, et al. 2007. Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus. J. Immunol. 178:1030-1038.
42. Price GE, et al. 2010. Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2, and H1N1 viruses. PLoS One 5:e13162. doi:10.1371/journal.pone.0013162.
43. Reed LJ, Muench H. 1938. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. (Lond.) (27):493-497.
44. Rowe T, et al. 1999. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J. Clin. Microbiol. 37:937-943.
45. Schimanski LM, et al. 2009. In vitro binding of HFE to the cationindependent mannose-6 phosphate receptor. Blood Cells Mol. Dis. 43: 180-193.
46. Schulman JL, Kilbourne ED. 1965. Induction of partial specific heterotypic immunity in mice by a single infection with influenza A virus. J. Bacteriol. 89:170-174.
47. Simmons CP, et al. 2007. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med. 4:e178. doi: 10.1371/journal.pmed.0040178.
48. Smith W, Andrewes CH, Liadlaw PP. 1933. A virus obtained from influenza patients. Lancet ii:66-68.
49. Song K, et al. 2010. Genetic immunization in the lung induces potent local and systemic immune responses. Proc. Natl. Acad. Sci. U. S. A. 107: 22213-22218.
50. Sonoguchi T, Naito H, Hara M, Takeuchi Y, Fukumi H. 1985. Crosssubtype protection in humans during sequential, overlapping, and/or concurrent epidemics caused by H3N2 and H1N1 influenza viruses. J. Infect. Dis. 151:81-88.
51. Stech J, Garn H, Wegmann M, Wagner R, Klenk HD. 2005. A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin. Nat. Med. 11:683-689.
52. Stevens J, et al. 2004. Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science 303:1866-1870.
53. Subbarao K, et al. 2003. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 305:192-200.
54. Subbarao K, Murphy BR, Fauci AS. 2006. Development of effective vaccines against pandemic influenza. Immunity 24:5-9.
55. Suguitan AL, Jr, et al. 2006. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med. 3:e360. doi:10.1371/journal.pmed.0030360.
56. Sun J, Madan R, Karp CL, Braciale TJ. 2009. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat. Med. 15:277-284.
57. Talon J, et al. 2000. Influenza A and B viruses expressing altered NS1 proteins: a vaccine approach. Proc. Natl. Acad. Sci. U. S. A. 97:4309-4314.
58. Tannock GA, Paul JA. 1987. Homotypic and heterotypic immunity of influenza A viruses induced by recombinants of the cold-adapted master strain A/Ann Arbor/6/60-ca. Arch. Virol. 92:121-133.
59. Taylor PM, Askonas BA. 1986. Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo. Immunology 58:417-420.
60. Taylor PM, Davey J, Howland K, Rothbard JB, Askonas BA. 1987. Class IMHCmolecules rather than other mouse genes dictate influenza epitope recognition by cytotoxic T cells. Immunogenetics 26:267-272.
61. Thomson CA, et al. 2012. Pandemic H1N1 influenza infection and vaccination in humans induces cross-protective antibodies that target the hemagglutinin stem. Front. Immunol. 3:87.
62. Townsend AR, Bastin J, Gould K, Brownlee GG. 1986. Cytotoxic T lymphocytes recognize influenza haemagglutinin that lacks a signal sequence. Nature 324:575-577.
63. Townsend AR, Gotch FM, Davey J. 1985. Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell 42:457-467.
64. Townsend AR, et al. 1986. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44:959-968.
65. Wang TT, et al. 2010. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog. 6:e1000796. doi:10.1371/journal. ppat.1000796.
66. Webster RG, Cox N, Stohr K. 2002. WHO manual on animal influenza diagnosis and surveillance. World Health Organization, Geneva, Switzerland.
67. Weinfurter JT, et al. 2011. Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates. PLoS Pathol. 7:e1002381. doi:10.1371/journal.ppat.1002381.
68. Wilkinson TM, et al. 2012. Preexisting influenza-specific CD4 T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 18:274-280.
69. Winter G, Fields S, Brownlee GG. 1981. Nucleotide sequence of the haemagglutinin gene of a human influenza virus H1 subtype. Nature 292:72-75.
70. Yap KL, Ada GL. 1978. The recovery of mice from influenza A virus infection: adoptive transfer of immunity with influenza virus-specific cytotoxic T lymphocytes recognizing a common virion antigen. Scand. J. Immunol. 8:413-420.